Outlook Therapeutics sets $485 LYTENAVA vial cost
Outlook Therapeutics, Inc. (OTLK) announced that it has established the wholesale acquisition cost for its product LYTENAVA™ in the United States at $485 per vial as of September 16, 2026.
Rhea-AI Filing Summary
Outlook Therapeutics, Inc. (OTLK) announced that it has established the wholesale acquisition cost for its product LYTENAVA™ in the United States at $485 per vial as of September 16, 2026. This disclosure sets an initial list price reference for LYTENAVA in the U.S. market.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Wholesale acquisition cost per vial of LYTENAVA: $485 per vial
1 metrics
Wholesale acquisition cost per vial of LYTENAVA
$485 per vial
Established in the United States as of September 16, 2026
Key Terms
wholesale acquisition cost, Emerging growth company, Exchange Act
3 terms
wholesale acquisition cost financial
"established the wholesale acquisition cost for LYTENAVA™ in the United States"
Wholesale acquisition cost (WAC) is the manufacturer’s published price for a drug sold to wholesalers before discounts, rebates or other price concessions; think of it as the sticker price a maker sets for bulk buyers. Investors track WAC because it affects a company’s reported revenue potential, pricing power and profit margins, and because deviations between WAC and the actual net price can signal competitive pressure, reimbursement changes, or hidden costs.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Exchange Act regulatory
"pursuant to Rule 14a-12 under the Exchange Act"
A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Does Outlook Therapeutics specify if $485 per vial is a wholesale acquisition cost or a different price type?
Outlook Therapeutics specifies that $485 per vial is the wholesale acquisition cost for LYTENAVA™ in the United States.
What is the trading symbol and exchange for Outlook Therapeutics common stock?
Outlook Therapeutics’ common stock trades under the symbol OTLK on The Nasdaq Stock Market LLC.
AI-generated analysis. How Rhea-AI works. Not financial advice.
